WO2009030373A1 - Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events - Google Patents

Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events Download PDF

Info

Publication number
WO2009030373A1
WO2009030373A1 PCT/EP2008/006858 EP2008006858W WO2009030373A1 WO 2009030373 A1 WO2009030373 A1 WO 2009030373A1 EP 2008006858 W EP2008006858 W EP 2008006858W WO 2009030373 A1 WO2009030373 A1 WO 2009030373A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
urate oxidase
prophylaxis
uric acid
rasburicase
Prior art date
Application number
PCT/EP2008/006858
Other languages
French (fr)
Inventor
Wolfgang Linz
Matthias Schaefer
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2010523299A priority Critical patent/JP2011509920A/en
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Priority to BRPI0816406A priority patent/BRPI0816406A2/en
Priority to NZ583635A priority patent/NZ583635A/en
Priority to AU2008295145A priority patent/AU2008295145B2/en
Priority to MX2010001976A priority patent/MX2010001976A/en
Priority to CN200880105379A priority patent/CN101801460A/en
Priority to MYPI2010000585A priority patent/MY183770A/en
Priority to CA2697929A priority patent/CA2697929A1/en
Priority to EP08785655A priority patent/EP2197550A1/en
Publication of WO2009030373A1 publication Critical patent/WO2009030373A1/en
Priority to ZA2010/00774A priority patent/ZA201000774B/en
Priority to US12/715,061 priority patent/US20100266567A1/en
Priority to IL204259A priority patent/IL204259A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to the use of urate oxidase, preferably recombinant urate oxidase, for example Rasburicase, for producing a medicament for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events, for example during and after cardiac surgery like CABG (coronary artery bypass graft), PCI (percutaneous coronary intervention), transplantation, post myocardial infarction and for the treatment or prophylaxis of coronary artery disease or heart failure, for example congestive heart failure.
  • CABG coronary artery bypass graft
  • PCI percutaneous coronary intervention
  • transplantation post myocardial infarction
  • post myocardial infarction for the treatment or prophylaxis of coronary artery disease or heart failure, for example congestive heart failure.
  • Uric acid is the end product of purine metabolism in birds, reptiles, primates and humans and is produced in the liver by oxidation of xanthine and hypoxanthine. In all other mammals, uric acid is further oxidized by the enzyme urate oxidase to allantoin. However, humans lack this enzyme. As uric acid has relatively poor water solubitlity, the increase in plasma levels of uric acid is known to be causative for several diseases such as gout. An acute elevation of uric acid leads to acute renal failure caused by the precipitation of crystals of uric acid in renal tubules (Ejaz A.A. et al., Clin. J. Am. Nephrol. (2007) 2:16-21).
  • Increase of uric acid production is caused in general in patients suffering from purine metabolism disorders such as hereditable hyperuricaemia.
  • purine metabolism disorders such as hereditable hyperuricaemia.
  • acute elevation of high levels of uric acid is also observed in any patient undergoing massive cell death such as during treatment of cancer with cytostatics. The latter is known to lead to the so-called tumor lysis syndrome where massive cell death leads to liberation of nucleic acids being rapidly catabolized into uric acid as the end product due to purine metabolism.
  • massive death of cells is also observed in any pathophysiological situation of ischemia and reperfusion and therefore also during cardiac surgery like CABG (coronary artery bypass graft), PCI (percutaneous coronary intervention), transplantation, post myocardial infarction, coronary artery disease or heart failure.
  • CABG coronary artery bypass graft
  • PCI percutaneous coronary intervention
  • Treatment with Benzbromaron enhances renal excretion of uric acid by targeting renal uric acid reabsorption.
  • the net effect under benzbromeron treatment is increased excretion of uric acid.
  • Treatment has to begin by subtreshold dosing since Benzbromarone itself can trigger the precipitation of uric acid in the kidney or urether.
  • Allopurinol Another approach targets the catabolism of purines into uric acid due to inhibition of xanthinoxidase, a key enzyme in purine metabolism: Allopurinol (4-hydroxypurinol), an analogue of xanthine, is an inhibitor of xanthinoxidase leading to decreased generation of uric acid. Treatment with Allopurinol is currently considered the standard pharmacological treatment for hyperuricemia-associated diseases such as gout. During treatment with Allopurinol, instead of uric acid, the precursors xanthines accumulate and are mainly excreted via the kidney.
  • Allopurinol Treatment with Allopurinol is preventive to avoid high uric acid levels but it is unsuitable in cases of already elevated uric acid levels and is moreover known to induce gout on its own. In case of prevention the tumor lysis syndrome during treatment of cancer, Allopurinol is given before cytotoxic treatment. Beside the application of allopurinol, management is directed to normalize metabolic abnormalities and preventing further renal damage. iii) Urate oxidase
  • Urate oxidase (Uric acid oxidase, urate oxygen oxidoreductase, EC 1.7.3.3) catalyses the oxidation of uric acid to allantoin, a water-soluble product that is easily excreted by the kidney (scheme 1).
  • the protein enzyme urate oxidase can, for example, be obtained from Aspergillus flavus.
  • the cDNA coding for this protein has been cloned and expressed in Escherichia coli (Legoux R. et al., J. Biol. Chem., 1992, 267, (12), 8565-8570), in Aspergillus flavus (Chevalet L. et al., Curr. Genet., 1992, 21 , 447-453) and in Saccharomyces cerevisiae (Leplatois P. et al., Gene., 1992, 122, 139-145).
  • Recombinant urate oxidase is urate oxidase produced by genetically modified microorganisms and can, for example, be obtained from the above mentioned genetically modified strains of Escherichia coli and Saccharomyces cerevisiae.
  • Rasburicase is a recombinant urate oxidase enzyme produced from genetically modified strain of Saccharomyces cerevisiae cloned with cDNA from a strain of Aspergillus flavus (Oldfield V et al., Drugs (2006) 66 (4):529-545, Leplatois P. et al., Gene., 1992, 122, 139-145).
  • Rasburicase is a tetrameric protein with identical subunits of a molecular mass of about 34 kDa each ( Figure 1) - similar to the native Aspergillus flavus urate oxidase (Bayol A. et al., Biotechnol. Appl. Biochem. 2002, 36, 21 -31).
  • Rasburicase Due to its mode of action, instead of treatment with allopurinol, use of Rasburicase is now the preferred treatment in situations of acute and massively increased plasma uric acid levels in the context of prevention of tumor lysis syndrome.
  • ROS reactive oxygen species
  • the invention relates to the use of an urate oxidase, preferably recombinant urate oxidase, for example Rasburicase, for producing a medicament for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events, for example during and after cardiac surgery like CABG (coronary artery bypass graft), PCI (percutaneous coronary intervention), transplantation, post myocardial infarction and for the treatment or prophylaxis of coronary artery disease or heart failure, for example congestive heart failure.
  • CABG coronary artery bypass graft
  • PCI percutaneous coronary intervention
  • transplantation post myocardial infarction
  • post myocardial infarction for the treatment or prophylaxis of coronary artery disease or heart failure, for example congestive heart failure.
  • additional treatment with a scavenger for H 2 O 2 is preferred, for example vitamins A, C or E, Trolox, Oligomere Proanthocyanidine, Gluthation, L-N- Acetylcystein, Ebselen, Lycopin, Flavonoid, Catechin und Anthocyan, more preferably L-ascorbic acid.
  • a scavenger for H 2 O 2 for example vitamins A, C or E, Trolox, Oligomere Proanthocyanidine, Gluthation, L-N- Acetylcystein, Ebselen, Lycopin, Flavonoid, Catechin und Anthocyan, more preferably L-ascorbic acid.
  • compositions comprise, as an active constituent, an effective dose of Rasburicase in addition to customary, pharmaceutically unobjectionable carriers and assistants and optionally also one or more other active pharmacological ingredients, for example ascorbic acid.
  • the pharmaceutical formulations contain normally from 0.1 to 90% by weight of Rasburicase.
  • the pharmaceutical formulations can be produced in a manner known per se. To this end, the active ingredients and/or their physiologically compatible salts, together with one or more solid or liquid pharmaceutical carriers and/or assistants, are converted to a suitable administration form or dosage form, which can then be used as a medicament in human medicine.
  • Medicaments which comprise Rasburicase can be administered, for example, parenterally, intravenously, rectally, nasally, by inhalation or topically, the preferred administration depending on the particular case.
  • excipients which are suitable for the desired pharmaceutical formulation are familiar to those skilled in the art on the basis of their expert knowledge.
  • solvents for example, antioxidants, dispersants, emulsifiers, antifoams, flavorings, preservatives, solubilizers, agents for achieving a depot effect, buffer substances or colorings.
  • the active compounds used are converted to solution, suspension or emulsion.
  • useful solvents are: water, physiological saline or alcohols, for example ethanol, propanol, glycerol, and additionally also sugar solutions such as glucose or mannitol solutions, or else a mixture of the different solvents mentioned.
  • suitable pharmaceutical formulations for administration in the form of aerosols or sprays are solutions, suspensions, emulsions or vesicular and micellar medicament forms of the active ingredients or their physiologically compatible salts in water or in a pharmaceutically unobjectionable water-miscible or oily solvent, or a mixture of such solvents.
  • suitable for administration in the form of aerosols or sprays, for example for nasal administration are powders of the active ingredients or their physiologically compatible salts.
  • all formulations may also comprise other pharmaceutical excipients such as isotonizing additives, surfactants, emulsifiers and stabilizers, and also a propellant gas.
  • the formulations mentioned may additionally be in the form of freeze-dried products.
  • the dosage of Rasburicase to be administered in accordance with the invention depends upon the individual case and, for optimal action, should be adjusted to the circumstances of the individual case as usual. For instance, it depends of course upon the frequency of administration and upon the potency and duration of action of the compounds used in each case for treatment or prophylaxis, but also upon the nature and severity of the disease to be treated, and also on the gender, age, weight and individual responsiveness of the human or animal to be treated, and upon whether acute or chronic treatment or prophylaxis is being practiced.
  • the dosage of Rasburicase may typically vary within the range from 1 mg to 1 g per day and per person (at body weight about 75 kg), preferably from 5 to 750 mg per day and person, for example from 100 to 150 mg per day and person. However, higher doses may also be appropriate.
  • the daily dose of the active ingredients may be administered all at once or it may be divided between a plurality of, for example 2, 3 or 4, administrations.
  • Example A Aqueous solution for intravenous administration To prepare 10 ml of solution comprising 50 ⁇ g of active compound per ml, 0,5 mg Rasburicase were dissolved in 10 ml of isotonic (0.9%) sodium chloride solution.
  • the isolated hearts of male Wistar rats were used which were purchased from our Laboratory Animal Science and Welfare (LASW).
  • the heart function was investigated on the "Isolated Working Heart” model as previously described (Itter G et al., Laboratory Animals (2005) 39; 178-193).
  • the hearts were first perfused according to Langendorff's method with an oxygenated (95% O 2 , 5% CO 2 ) noncirculating Krebs-Henseleit solution of the following compositions (mmol/L): NaCI, 118; KCI, 4.7; CaCI 2 , 2.5; MgSO 4 , 1.6; NaHCO 3 , 24.9; KH 2 PO 4 , 1.2; glucose, 5.5; Na-pyruvate, 2.0.
  • a catheter placed into the pulmonary artery drained the coronary effluent perfusate that was collected for determination of coronary flow and venous PQ 2 measurements.
  • the left atrium was cannulated by an incision of the left auricle. After a 15-minute equilibration period at a fixed perfusion pressure of 60 mmHg, the heart was switched into the working mode at a fixed filling pressure of 11 mmHg.
  • Coronary flow (CF) and pressure signals (dP/dt max ) were sampled at 500 Hz, averaged every 2 seconds.
  • Table 1 shows that concentrations higher than 100 ⁇ M H 2 O 2 strongly reduced coronary flow and contractility.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The invention relates to the use of an urate oxidase, preferably recombinant urate oxidase, for example Rasburicase, for producing a medicament for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events, for example during and after cardiac surgery like CABG (coronary artery bypass graft), PCI (percutaneous coronary intervention), transplantation, post myocardial infarction and for the treatment or prophylaxis of coronary artery disease or heart failure, for example congestive heart failure.

Description

Description
Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events
The invention relates to the use of urate oxidase, preferably recombinant urate oxidase, for example Rasburicase, for producing a medicament for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events, for example during and after cardiac surgery like CABG (coronary artery bypass graft), PCI (percutaneous coronary intervention), transplantation, post myocardial infarction and for the treatment or prophylaxis of coronary artery disease or heart failure, for example congestive heart failure.
Uric acid is the end product of purine metabolism in birds, reptiles, primates and humans and is produced in the liver by oxidation of xanthine and hypoxanthine. In all other mammals, uric acid is further oxidized by the enzyme urate oxidase to allantoin. However, humans lack this enzyme. As uric acid has relatively poor water solubitlity, the increase in plasma levels of uric acid is known to be causative for several diseases such as gout. An acute elevation of uric acid leads to acute renal failure caused by the precipitation of crystals of uric acid in renal tubules (Ejaz A.A. et al., Clin. J. Am. Nephrol. (2007) 2:16-21).
Increase of uric acid production is caused in general in patients suffering from purine metabolism disorders such as hereditable hyperuricaemia. However, acute elevation of high levels of uric acid is also observed in any patient undergoing massive cell death such as during treatment of cancer with cytostatics. The latter is known to lead to the so-called tumor lysis syndrome where massive cell death leads to liberation of nucleic acids being rapidly catabolized into uric acid as the end product due to purine metabolism. In general massive death of cells is also observed in any pathophysiological situation of ischemia and reperfusion and therefore also during cardiac surgery like CABG (coronary artery bypass graft), PCI (percutaneous coronary intervention), transplantation, post myocardial infarction, coronary artery disease or heart failure.
Beside the latter mentioned acute insults, increased plasma uric acid concentrations were recently found to be predictive also for mortality in congestive heart failure (Anker SD et al., Circulation (2003); 107:1991-1997). A causative correlation for this has been also discussed recently (Hare JM et al., Circulation (2003) 107:1951-1953).
Currently three different principles can be used in order to reduce pathophysiological elevated levels of uric acid, (i) Enhancement of renal excretion of uric acid, (ii) impairment of uric acid generation or (iii) conversion of uric acid into allantoin.
i) Benzbromaron
Treatment with Benzbromaron ((2-Ethyl-3-benzofuranyl)-(3,5-dibrom-4-hydroxyphenyl) keton) enhances renal excretion of uric acid by targeting renal uric acid reabsorption. The net effect under benzbromeron treatment is increased excretion of uric acid.
Treatment has to begin by subtreshold dosing since Benzbromarone itself can trigger the precipitation of uric acid in the kidney or urether.
ii) Allopurinol Another approach targets the catabolism of purines into uric acid due to inhibition of xanthinoxidase, a key enzyme in purine metabolism: Allopurinol (4-hydroxypurinol), an analogue of xanthine, is an inhibitor of xanthinoxidase leading to decreased generation of uric acid. Treatment with Allopurinol is currently considered the standard pharmacological treatment for hyperuricemia-associated diseases such as gout. During treatment with Allopurinol, instead of uric acid, the precursors xanthines accumulate and are mainly excreted via the kidney. Treatment with Allopurinol is preventive to avoid high uric acid levels but it is unsuitable in cases of already elevated uric acid levels and is moreover known to induce gout on its own. In case of prevention the tumor lysis syndrome during treatment of cancer, Allopurinol is given before cytotoxic treatment. Beside the application of allopurinol, management is directed to normalize metabolic abnormalities and preventing further renal damage. iii) Urate oxidase
The mechanism of action of urate oxidase is different from Allopurinol. Urate oxidase (Uric acid oxidase, urate oxygen oxidoreductase, EC 1.7.3.3) catalyses the oxidation of uric acid to allantoin, a water-soluble product that is easily excreted by the kidney (scheme 1). The protein enzyme urate oxidase can, for example, be obtained from Aspergillus flavus.
The cDNA coding for this protein has been cloned and expressed in Escherichia coli (Legoux R. et al., J. Biol. Chem., 1992, 267, (12), 8565-8570), in Aspergillus flavus (Chevalet L. et al., Curr. Genet., 1992, 21 , 447-453) and in Saccharomyces cerevisiae (Leplatois P. et al., Gene., 1992, 122, 139-145).
Recombinant urate oxidase is urate oxidase produced by genetically modified microorganisms and can, for example, be obtained from the above mentioned genetically modified strains of Escherichia coli and Saccharomyces cerevisiae. Rasburicase is a recombinant urate oxidase enzyme produced from genetically modified strain of Saccharomyces cerevisiae cloned with cDNA from a strain of Aspergillus flavus (Oldfield V et al., Drugs (2006) 66 (4):529-545, Leplatois P. et al., Gene., 1992, 122, 139-145). Rasburicase is a tetrameric protein with identical subunits of a molecular mass of about 34 kDa each (Figure 1) - similar to the native Aspergillus flavus urate oxidase (Bayol A. et al., Biotechnol. Appl. Biochem. 2002, 36, 21 -31).
Guanine Hypoxanthine
Guanine deaminase \ / Xanthine oxidase Allopurinol
Xanthine
Xanthine oxidase >/≤ Oxipurinol
Urinary excretion Uric acid
Urate oxidase / Rasburicase
5-hydroxyisourate
Nonenzymatic degradation
Urinary excretion Allantoin
H2O2
Scheme 1 : Effects of urate oxidase, Rasburicase, Allopurinol and Oxipurinol (the active metabolite of Allopurinol) on purine catabolism. Θ indicates inhibition of xanthine oxidase by allopurinol and oxipurinol;© indicates metabolism of uric acid by Rasburicase or Urate Oxidase
Due to its mode of action, instead of treatment with allopurinol, use of Rasburicase is now the preferred treatment in situations of acute and massively increased plasma uric acid levels in the context of prevention of tumor lysis syndrome.
An apparent disadvantage of urate oxidase treatment is the generation of a stoichiometrically equivalent amount of hydrogenperoxide (Scheme 2), which is according to current knowledge seen as a problem especially in regard of the intended use of urate oxidase in cardiovascular indications.
Urate oxidase/Rasburicase
Uric acid + 2 H2O + O2 Allantoin + 2 H2O2 + CO2 Scheme 2 H2O2 although not a radical itself, can easily be converted into hydroxyl radicals by Fenton reaction. Different species of endogenously generated oxygen radicals are termed as reactive oxygen species (ROS) comprising also other types such as hydroxyl radicals or superoxide anions which are easily converted. Those ROS can be generated by different cellular enzyme systems, for example by NADPH oxidase. In the past ROS were shown to be involved in many physiological and pathophysiological processes. Numerous studies revealed a detrimental role of ROS in regard to cardiovascular indications (Lo SK et al., Am. J. Physiol (1993) 264:L406-412; PMNs; Gasic AC et al., Circulation (1991) Nov; 84(5): 2154-2166; Bradley JR et al., Am. J. Pathol. (1995); 147(3): 627-641 ; Kevil CG et al., Am. J. Physiol. Cell Physiol. (2000) JuI; 279(1): C21 -30; Zafari AM et al., Hypertension (1998) Sep; 32(3): 488-495; for an overview see Cai H, Cardiovascular Research (2005) 68:26-36).
Experiments have been carried out to test the urate oxidase Rasburicase in combination with uric acid for its expected adverse cardiac effects caused by the generated hydrogen peroxide. Suprisingly, the experiments have shown that the heart function is not significantly affected by high concentrations of Rasburicase alone or in combination with high concentrations of uric acid. Furthermore, the combination of Rasburicase and uric acid even improved heart function and the cardiodynamics when the combination is present prior and during ischemia and reperfusion.
Therefore, the invention relates to the use of an urate oxidase, preferably recombinant urate oxidase, for example Rasburicase, for producing a medicament for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events, for example during and after cardiac surgery like CABG (coronary artery bypass graft), PCI (percutaneous coronary intervention), transplantation, post myocardial infarction and for the treatment or prophylaxis of coronary artery disease or heart failure, for example congestive heart failure.
In another embodiment additional treatment with a scavenger for H2O2 is preferred, for example vitamins A, C or E, Trolox, Oligomere Proanthocyanidine, Gluthation, L-N- Acetylcystein, Ebselen, Lycopin, Flavonoid, Catechin und Anthocyan, more preferably L-ascorbic acid.
Pharmaceutical formulations comprise, as an active constituent, an effective dose of Rasburicase in addition to customary, pharmaceutically unobjectionable carriers and assistants and optionally also one or more other active pharmacological ingredients, for example ascorbic acid. The pharmaceutical formulations contain normally from 0.1 to 90% by weight of Rasburicase.
The pharmaceutical formulations can be produced in a manner known per se. To this end, the active ingredients and/or their physiologically compatible salts, together with one or more solid or liquid pharmaceutical carriers and/or assistants, are converted to a suitable administration form or dosage form, which can then be used as a medicament in human medicine.
Medicaments which comprise Rasburicase can be administered, for example, parenterally, intravenously, rectally, nasally, by inhalation or topically, the preferred administration depending on the particular case.
The excipients which are suitable for the desired pharmaceutical formulation are familiar to those skilled in the art on the basis of their expert knowledge. In addition to solvents, gel formers, suppository bases, tablet excipients and other active ingredient carriers, it is possible to use, for example, antioxidants, dispersants, emulsifiers, antifoams, flavorings, preservatives, solubilizers, agents for achieving a depot effect, buffer substances or colorings.
For subcutaneous, intramuscular or intravenous administration, the active compounds used, if desired with the substances customary for this purpose, such as solubilizers, emulsifiers or further excipients, are converted to solution, suspension or emulsion. Examples of useful solvents are: water, physiological saline or alcohols, for example ethanol, propanol, glycerol, and additionally also sugar solutions such as glucose or mannitol solutions, or else a mixture of the different solvents mentioned. Examples of suitable pharmaceutical formulations for administration in the form of aerosols or sprays are solutions, suspensions, emulsions or vesicular and micellar medicament forms of the active ingredients or their physiologically compatible salts in water or in a pharmaceutically unobjectionable water-miscible or oily solvent, or a mixture of such solvents. Also suitable for administration in the form of aerosols or sprays, for example for nasal administration, are powders of the active ingredients or their physiologically compatible salts. If required, all formulations may also comprise other pharmaceutical excipients such as isotonizing additives, surfactants, emulsifiers and stabilizers, and also a propellant gas. The formulations mentioned may additionally be in the form of freeze-dried products.
The dosage of Rasburicase to be administered in accordance with the invention depends upon the individual case and, for optimal action, should be adjusted to the circumstances of the individual case as usual. For instance, it depends of course upon the frequency of administration and upon the potency and duration of action of the compounds used in each case for treatment or prophylaxis, but also upon the nature and severity of the disease to be treated, and also on the gender, age, weight and individual responsiveness of the human or animal to be treated, and upon whether acute or chronic treatment or prophylaxis is being practiced.
The dosage of Rasburicase may typically vary within the range from 1 mg to 1 g per day and per person (at body weight about 75 kg), preferably from 5 to 750 mg per day and person, for example from 100 to 150 mg per day and person. However, higher doses may also be appropriate. The daily dose of the active ingredients may be administered all at once or it may be divided between a plurality of, for example 2, 3 or 4, administrations.
Experimental part
List of abbreviations
Asc.A Ascorbic acid kDa Kilo Dalton n Number of animals
P Pressure
Rasb Rasburicase
Reperf. Reperfusion
UA Uric acid
Examples of pharmaceutical preparations
Example A: Aqueous solution for intravenous administration To prepare 10 ml of solution comprising 50 μg of active compound per ml, 0,5 mg Rasburicase were dissolved in 10 ml of isotonic (0.9%) sodium chloride solution.
Experiments on isolated working rat hearts
As biological materials the isolated hearts of male Wistar rats were used which were purchased from our Laboratory Animal Science and Welfare (LASW). The heart function (coronary flow and contractility) was investigated on the "Isolated Working Heart" model as previously described (Itter G et al., Laboratory Animals (2005) 39; 178-193).The hearts were first perfused according to Langendorff's method with an oxygenated (95% O2, 5% CO2) noncirculating Krebs-Henseleit solution of the following compositions (mmol/L): NaCI, 118; KCI, 4.7; CaCI2, 2.5; MgSO4, 1.6; NaHCO3, 24.9; KH2PO4, 1.2; glucose, 5.5; Na-pyruvate, 2.0. A catheter placed into the pulmonary artery drained the coronary effluent perfusate that was collected for determination of coronary flow and venous PQ2 measurements. The left atrium was cannulated by an incision of the left auricle. After a 15-minute equilibration period at a fixed perfusion pressure of 60 mmHg, the heart was switched into the working mode at a fixed filling pressure of 11 mmHg. Coronary flow (CF) and pressure signals (dP/dtmax) were sampled at 500 Hz, averaged every 2 seconds.
Effects on coronary flow and contractility of the heart: High Rasburicase concentrations were tested in combination with different uric acid concentrations on isolated working rat hearts for their possible adverse cardiac effects caused by the generated hydrogenperoxide (H2O2).
Table 1 shows that concentrations higher than 100 μM H2O2 strongly reduced coronary flow and contractility.
Table 1 : Effect of increasing H2O2 concentrations on coronary flow (CF) and contractility (dP/dtmax) in isolated rat hearts; n = 4, *p<0.05 vs basal value
Figure imgf000010_0001
Increasing Rasburicase concentrations (0.5, 1.5, 5, 15, 50μg/mL) induced only a slight (not significant) decrease in coronary flow and contractility, which was not influenced in the presence of uric acid (6 mg/L) (Tab. 2). Similar effects were observed when high Rasburicase (50/yg/mL) was perfused with higher concentrations of uric acid (6-30 mg/L) (Tab. 3).
Table 2: Effect of increasing Rasburicase concentrations with and without Uric Acid (UA 6 mg/L) on coronary flow (CF) and contractility (dP/dtmax) in isolated rat hearts; n=6-7/Group
Figure imgf000010_0002
Figure imgf000011_0001
Table 3: Effect of increasing Uric Acid and high Rasburicase (Rasb 50 μg/ml_) concentrations on coronary flow (CF) and contractility (dP/dtmax) in isolated rat hearts; n=4-5/Group
Figure imgf000011_0002
Effects on coronary flow and contractility of the heart with global ischemia and reperfusion:
High Rasburicase (50 /yg/mL) in combination with high uric acid concentrations (15 or 30 mg/L), concentration-dependently improved the recovery after ischemia/reperfusion (Tab. 4, 5).
Table 4: Effect of high Rasburicase (Rasb 50 /yg/mL) and Uric Acid (UA 15 mg/L) concentrations on coronary flow (CF) and contractility (dP/dtmax) in isolated rat hearts with global ischemia and reperfusion; n=5/Group; *p<0.05 vs Control
Figure imgf000012_0001
Table 5: Effect of high Rasburicase (Rasb 50 μg/mL) and Uric Acid (UA 30 mg/L) concentrations on coronary flow (CF) and contractility (dP/dtmaχ) in isolated rat hearts with global ischemia and reperfusion; n=5/Group; *p<0.05 vs Control
Figure imgf000013_0001
Addition of ascorbic acid (1 mM) led to a normalization of coronary flow and a further improvement on contractility after ischemia/reperfusion (Tab. 6).
Table 6: Effect of high Rasburicase (Rasb 50 μg/ml_), Uric Acid (UA 30 mg/L) and Ascorbic Acid (Asc.A. 1 mM) concentrations on coronary flow (CF) and contractility (dP/dtmaχ) in isolated rat hearts with global ischemia and reperfusion; n=6/Group; *p<0.05 vs Control
Figure imgf000014_0001
As shown above heart function was not significantly affected by high concentrations of Rasburicase alone or in combination with high concentrations of uric acid. Suprisingly, the use of Rasburicase in the presence of uric acid even improved heart function when present prior and during ischemia/reperfusion. In the scenario of cardiac surgery and heart failure, treatment with Rasburicase is assumed to be suitable and safe. In our ischemia/reperfusion experiments Rasburicase even improved cardiodynamics after ischemia.

Claims

Claims
1. The use of urate oxidase for producing a medicament for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events.
2. The use of urate oxidase according to claim 1 for producing a medicament for the treatment or prophylaxis of heart failure.
3. The use of urate oxidase according to claims 1 or 2 for producing a medicament for the treatment or prophylaxis of congestive heart failure.
4. The use of urate oxidase according to claim 1 for producing a medicament for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events during and after cardiac surgery.
5. The use of urate oxidase according to claim 1 or 4 for producing a medicament for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events during and after coronary artery bypass graft, percutaneous coronary intervention or transplantation.
6. The use of urate oxidase according to claim 1 for producing a medicament for the treatment or prophylaxis of myocardial infarction.
7. The use according to claims 1 to 6, wherein urate oxidase is a recombinant urate oxidase.
8. The use according to claims 1 to 7, wherein urate oxidase is Rasburicase.
9. The use according to claims 1 to 8 together with a H2O2 scavenger.
10. The use according to claim 9 wherein the H2O2 scavenger is ascorbic acid.
PCT/EP2008/006858 2007-09-05 2008-08-20 Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events WO2009030373A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN200880105379A CN101801460A (en) 2007-09-05 2008-08-20 Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events
BRPI0816406A BRPI0816406A2 (en) 2007-09-05 2008-08-20 use of urate oxidase for the treatment or prophylaxis of indirect heart disorders or sequelae caused by ischemic or reperfusion events.
NZ583635A NZ583635A (en) 2007-09-05 2008-08-20 Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events
AU2008295145A AU2008295145B2 (en) 2007-09-05 2008-08-20 Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events
MX2010001976A MX2010001976A (en) 2007-09-05 2008-08-20 Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events.
JP2010523299A JP2011509920A (en) 2007-09-05 2008-08-20 Use of urate oxidase for the treatment or prevention of cardiac damage or indirect sequelae caused by ischemia or reperfusion events
MYPI2010000585A MY183770A (en) 2007-09-05 2008-08-20 Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events
CA2697929A CA2697929A1 (en) 2007-09-05 2008-08-20 Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events
EP08785655A EP2197550A1 (en) 2007-09-05 2008-08-20 Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events
ZA2010/00774A ZA201000774B (en) 2007-09-05 2010-02-02 Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events
US12/715,061 US20100266567A1 (en) 2007-09-05 2010-03-01 Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events
IL204259A IL204259A (en) 2007-09-05 2010-03-02 Use of rasburicase for producing a medicament for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07291072.2 2007-09-05
EP07291072 2007-09-05
US1524007P 2007-12-20 2007-12-20
US61/015,240 2007-12-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/715,061 Continuation US20100266567A1 (en) 2007-09-05 2010-03-01 Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events

Publications (1)

Publication Number Publication Date
WO2009030373A1 true WO2009030373A1 (en) 2009-03-12

Family

ID=38713162

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/006858 WO2009030373A1 (en) 2007-09-05 2008-08-20 Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events

Country Status (22)

Country Link
US (1) US20100266567A1 (en)
EP (1) EP2197550A1 (en)
JP (1) JP2011509920A (en)
KR (1) KR20100053609A (en)
CN (1) CN101801460A (en)
AR (1) AR068360A1 (en)
AU (1) AU2008295145B2 (en)
BR (1) BRPI0816406A2 (en)
CA (1) CA2697929A1 (en)
CL (1) CL2008002623A1 (en)
CO (1) CO6260090A2 (en)
IL (1) IL204259A (en)
MA (1) MA31624B1 (en)
MX (1) MX2010001976A (en)
MY (1) MY183770A (en)
NZ (1) NZ583635A (en)
PA (1) PA8794801A1 (en)
PE (1) PE20090642A1 (en)
TW (1) TW200927929A (en)
UY (1) UY31320A1 (en)
WO (1) WO2009030373A1 (en)
ZA (1) ZA201000774B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114972A (en) * 1990-07-30 1992-05-19 Tsuyoshi Ohnishi Synthesis and uses of new ascorbic acid derivatives which have anti-oxidant and anti-cancer activities
WO2002000210A2 (en) * 2000-06-28 2002-01-03 Merck & Co., Inc. Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
WO2004026118A2 (en) * 2002-09-20 2004-04-01 Oregon Health & Science University Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries
WO2005077042A2 (en) * 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Albumin fusion proteins
US20050232902A1 (en) * 2004-04-17 2005-10-20 Theodoros Kofidis Injectable bioartificial tissue matrix

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070197512A1 (en) * 2006-01-27 2007-08-23 Japan Tobacco Inc. Carboxylic Acid Compounds and Use Thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114972A (en) * 1990-07-30 1992-05-19 Tsuyoshi Ohnishi Synthesis and uses of new ascorbic acid derivatives which have anti-oxidant and anti-cancer activities
WO2002000210A2 (en) * 2000-06-28 2002-01-03 Merck & Co., Inc. Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
WO2004026118A2 (en) * 2002-09-20 2004-04-01 Oregon Health & Science University Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries
WO2005077042A2 (en) * 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Albumin fusion proteins
US20050232902A1 (en) * 2004-04-17 2005-10-20 Theodoros Kofidis Injectable bioartificial tissue matrix

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP2197550A1 *
WATANABE S ET AL: "Reducing uric acid as a means to prevent cardiovascular and renal disease", EXPERT OPINION ON THERAPEUTIC PATENTS 2002 UNITED KINGDOM, vol. 12, no. 2, 2002, pages 193 - 199, XP002463234, ISSN: 1354-3776 *

Also Published As

Publication number Publication date
PE20090642A1 (en) 2009-06-18
BRPI0816406A2 (en) 2017-05-16
MX2010001976A (en) 2010-03-10
PA8794801A1 (en) 2009-04-23
US20100266567A1 (en) 2010-10-21
CL2008002623A1 (en) 2009-01-16
AU2008295145B2 (en) 2013-12-05
UY31320A1 (en) 2009-04-30
CN101801460A (en) 2010-08-11
AU2008295145A1 (en) 2009-03-12
AR068360A1 (en) 2009-11-11
IL204259A (en) 2013-06-27
TW200927929A (en) 2009-07-01
CA2697929A1 (en) 2009-03-12
MA31624B1 (en) 2010-08-02
ZA201000774B (en) 2011-04-28
EP2197550A1 (en) 2010-06-23
CO6260090A2 (en) 2011-03-22
KR20100053609A (en) 2010-05-20
MY183770A (en) 2021-03-12
NZ583635A (en) 2011-06-30
JP2011509920A (en) 2011-03-31
RU2010112867A (en) 2011-10-10

Similar Documents

Publication Publication Date Title
US8852582B2 (en) Compositions comprising glutathione reductase and oxidized glutathione
JP4842247B2 (en) Treatment of metabolic diseases using malonyl-CoA decarboxylase inhibitors
Iskesen et al. Trimetazidine reduces oxidative stress in cardiac surgery
KR100363069B1 (en) Pharmaceutical compositions containing hydroxamic acid derivatives
JP4727578B2 (en) Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors
HU225109B1 (en) Pharmaceutical compositions comprising antioxidant salen-metal complex and their use
Belardinelli et al. Oxidative stress, endothelial function and coenzyme Q_ {10}
Zou et al. Protective role of α-lipoic acid in hyperuricemia-induced endothelial dysfunction
JP4648317B2 (en) Piperidine compounds useful as malonyl-CoA decarboxylase inhibitors
Rodríguez-Graciani et al. Association between L-OPA1 cleavage and cardiac dysfunction during ischemia-reperfusion injury in rats
Chen et al. Doxorubicin-induced cardiac toxicity is mediated by lowering of peroxisome proliferator-activated receptor δ expression in rats
Pantos et al. Thyroid hormone at supra-physiological dose optimizes cardiac geometry and improves cardiac function in rats with old myocardial infarction
Türck et al. Trapidil improves hemodynamic, echocardiographic and redox state parameters of right ventricle in monocrotaline-induced pulmonary arterial hypertension model
AU2008295145B2 (en) Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events
RU2482187C2 (en) Use of rasburicase for treating or preventing cardiac disorders or indirect complications caused by ischemic strokes or reperfusion
CZ74199A3 (en) Agent for increasing activity of glutathione reductase
EP1361885B1 (en) Use of gamma-gt inhibitors for the treatment of chronic degenerative diseases
EP3876933B1 (en) Neutrophil inflammation inhibitor and uses thereof
US20230055500A1 (en) Composition for preventing or treating ischemia reperfusion injury comprising nadph oxidase 1 inhibitor as active ingredient
JP6364362B2 (en) Human chymase inhibitor and functional food, and method for inhibiting human chymase activity
Fletcher et al. Cyclosporine A induced changes to plasma and erythrocyte antioxidant defences
US20200155493A1 (en) Pharmaceutical composition for treating excessive lactate production and acidemia
NAKAJIMA et al. Studies on the Control of Plant Diseses by Amino Acid Derivatives (IV) Effect of sodium N-Lauroyl-L-valinate on the metabolism of rice blast fungus
Jolliet et al. Heat shock proteins in critical illness: markers of cellular stress or more?
KR20110036314A (en) Compositions for treatment of mitochondrial diseases comprising a compound of formula i or their pharmaceutically acceptable salts as an effective compound

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880105379.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08785655

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12010500265

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/001976

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 10021841

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2697929

Country of ref document: CA

Ref document number: 2008785655

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 583635

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 204259

Country of ref document: IL

Ref document number: 2008295145

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2010523299

Country of ref document: JP

Kind code of ref document: A

Ref document number: 20107004878

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1229/CHENP/2010

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: PI 2010000585

Country of ref document: MY

ENP Entry into the national phase

Ref document number: 2008295145

Country of ref document: AU

Date of ref document: 20080820

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2010000174

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2010112867

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0816406

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100304